PARICALCITOL

Peak

paricalcitol

NDAINTRAVENOUSSOLUTION
Approved
Feb 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

synthetic, biologically active vitamin D 2 analog. Preclinical and in vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the vitamin D receptor (VDR), which results in the selective activation of vitamin D responsive pathways. Vitamin D and…

Pharmacologic Class:

Vitamin D2 Analog

Clinical Trials (5)

NCT04064827Phase 3Terminated

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Started Sep 2020
2 enrolled
Chronic Kidney Disease (CKD)Secondary Hyperparathyroidism (SHPT)
NCT03883919Phase 1Completed

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

Started Jul 2019
20 enrolled
Pancreatic CancerPancreas CancerCancer of the Pancreas
NCT03588884Phase 4Completed

Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency

Started Jun 2018
NCT03415854Phase 2Completed

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

Started Jan 2018
11 enrolled
Pancreatic CancerPancreatic Ductal AdenocarcinomaPancreatic Adenocarcinoma+2 more
NCT01939977Phase 4Completed

Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.

Started Jan 2014
148 enrolled
Secondary Hyperparathyroidism Due to Renal Causes